The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Peripheral Neuropathy after Induction Chemotherapy before Autologous Peripheral Blood Stem Cell Transplantation in a Patient with Multiple Myeloma with Amyloidosis Treated with Complex Korean Medicine Treatment

아밀로이드증을 동반한 다발골수종 환자의 자가말초혈액조혈모세포 이식 전 유도항암화학요법 후 발생한 말초신경병증에 대한 복합 한의 치험 1례

  • Mariah Kim (Korean Medicine Hospital of Pusan National University) ;
  • Seyeon Lee (Korean Medicine Hospital of Pusan National University) ;
  • Kibeom Ku (Korean Medicine Hospital of Pusan National University) ;
  • Irang Nam (Korean Medicine Hospital of Pusan National University) ;
  • Minhwa Kim (Korean Medicine Hospital of Pusan National University) ;
  • So-yeon Kim (Korean Medicine Hospital of Pusan National University)
  • Received : 2023.09.19
  • Accepted : 2023.10.20
  • Published : 2023.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: We present a case of multiple myeloma with amyloidosis, which has features of peripheral neuropathy after induction chemotherapy before autologous peripheral blood stem cell transplantation, in a 56-year-old woman with Korean medicine. Case Presentation: For 17 days of hospitalization, the patient with complaints of numbness and a tingling sensation in the hands and feet was treated with acupuncture, herbal medicine. To reduce the symptoms, we provided Korean medicine treatments, including herbal medicine, acupuncture, and moxibustion. The Visual Analog Scale (VAS) was used to evaluate the results of the treatment. Until discharge, the VAS scores decreased for both hands and the foot tingling sensation. Conclusion: According to these results, Korean medicine treatment may be considered an effective treatment for tingling sensations in a patient with multiple myeloma with amyloidosis. Prospective studies are needed in the future to confirm and expand these findings.

Keywords

Acknowledgement

본 연구는 2022년도 부산대학교병원 임상연구비 지원으로 이루어졌음.

References

  1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374(9686):324-39. https://doi.org/10.1016/S0140-6736(09)60221-X
  2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32(1):45-59.
  3. Wang AK, Fealey RD, Gehrking TL, Low PA. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc 2008;83(11):1226-30. https://doi.org/10.4065/83.11.1226
  4. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112(5):1593-9. https://doi.org/10.1182/blood-2008-04-149385
  5. Park JH, Jung IC, Lee SH, Lee JS, Bae KR, Cho CK, et al. Preliminary study to develop an instrument for pattern identification and evaluation for chemotherapy-induced peripheral neuropathy (CIPN). The Journal of Internal Korean Medicine 2016;37(1):77-89. https://doi.org/10.22246/jikm.2016.37.4.631
  6. Association of Korean Medicine Professors for Cardiovascular and Neurological Medicine. Cardiovascular and Neurological Medicine in Korean Medicine I. Seoul: Wooripub; 2018, p. 289-308.
  7. Alexanian R, Fraschini G, Smith L. Amyloidosis in multiple myeloma or without apparent cause. Arch Intern Med 1984;144(11):2158-60. https://doi.org/10.1001/archinte.1984.04400020060009
  8. Kim HJ, Moon SJ, Kim HJ, Choi HY, Ryu DR, Yoo TH, et al. Clinical Science : Clinical Characteristics of Amyloidosis. Kidney Research and Clinical Practice 2005;24(2):230-8.
  9. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002 Jun;99(12):4276-82. https://doi.org/10.1182/blood.V99.12.4276
  10. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. N Engl J Med 2007 Jun;357(11):1083-93. https://doi.org/10.1056/NEJMoa070484
  11. Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol 2013;4:156.
  12. Kono T, Mamiya N, Chisato N, Ebisawa Y, Yamazaki H, Watari J, et al. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evidence-based complementary and alternative medicine 2011;2011:418481.
  13. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113-20. pmid:16754936. https://doi.org/10.1200/JCO.2005.04.7779
  14. Kyle RA, Kelly JJ, Dyck PJ. Amyloidosis and neuropathy. In: PJ Dyck, PK Thomas, eds. Peripheral Neuropathy. 4th ed. Philadelphia, PA: Elsevier Saunders; 2005, p. 2427-51.
  15. Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol 2017;8:86.
  16. Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm 2014;71(1):19-25. https://doi.org/10.2146/ajhp130126
  17. Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, et al. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy:A multicenter collaborative study. Experimental and therapeutic medicine 2012;3(1):60-5. https://doi.org/10.3892/etm.2011.375
  18. Nationwide College of Korean Medicine Faculty Council of Cardiology Internal Medicine. Cardiovascular and Neurological Medicine in Korean Medicine Seoul: Woori pub; 2016, p. 273-82.
  19. Lee JH, Park HL, Lee HY, Cho MK, Hong MN, Han CW, et al. Case Report of Chemotherapy Induced Peripheral Neuropathy Treated with Korean Medicine. Korean J Oriental Physiology & Pathology 2014;28(5):565-70.